Celera Genomics Signs Emory University and Van Andel Institute to Database Subscriptions.

Business Editors, Health/Medical Writers

ROCKVILLE, Md.--(BW HealthWire)--March 30, 2001

The University of Texas M. D. Anderson Cancer Center

Signs Onto Existing UT Southwestern Subscription

Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today it signed multi-year agreements with Emory University in Georgia and the Van Andel Institute in Michigan, which allows these investigators access to all of Celera's database products. The subscribers will access Celera's database information through its Celera Discovery System(TM). The University of Texas M.D. Anderson Cancer Center in Houston now also has access to the Celera databases as part of the existing University of Texas Southwestern Medical Center at Dallas subscription deal signed with Celera in July 2000. Financial terms of the agreements were not disclosed.

"We believe that in this new era of genomics research, the Celera Discovery System continues to provide the necessary tools and integrated data to enable researchers around the world, including these latest preeminent institutions, to advance their research programs and make important discoveries to improve human health," said J. Craig Venter, Ph.D., Celera's president and chief scientific officer.

The Celera Discovery System is an integrated, web-based discovery system that enables users to leverage Celera's computational tools, super-computing power, and the genomic and biological data to advance the discovery process for researchers worldwide.

About Emory University and the Robert W. Woodruff Health Sciences

Center

Emory University's Woodruff Health Sciences Center includes the schools of medicine, public health and nursing, as well as the Yerkes Regional Primate Research Center and Emory Healthcare. Emory University also includes Emory College, Oxford College, the Graduate School of Arts and Sciences, and schools of business, law and theology. Emory's Health Sciences Center is nationally recognized for its programs in education, research and patient care, and its professional schools are ranked among the top in the nation. Along with its health care affiliates, Emory is one of the largest and most influential providers of patient care in Atlanta and the region. Within the School of Medicine, several departments rank in the top 10 in the nation in NIH funding. New Emory facilities in genomics include the Core Facility for Functional Genomics, serving all universities within the Georgia Research Alliance, an alliance of industry, government and leading research universities. The Joseph B. Whitehead Research Building, scheduled for completion in 2001, will house a new Center for Medical Genomics, expected to lead the university in new genetic discoveries. Emory's Winship Cancer Institute is building a significant program in cancer genomics research, along with a new building scheduled to open in 2002 that will serve as a "discovery accelerator" for bringing individualized genomics-based treatments to patients. The institute recently became a partner in the Georgia Cancer Coalition, a public-private partnership of hospitals, universities, biotech firms, civic groups and government agencies allied to prevent, treat and save lives from cancer. Emory scientists in neurology, psychiatry, pharmacology, urology and gastroenterology also are using genomics technologies to advance discoveries in basic science, diagnostics and drug discovery.

About Van Andel Institute

The Van Andel Institute was created in 1996 by Jay and Betty Van Andel in Grand Rapids, Michigan, as their lasting legacy that would enrich lives and enhance the health of generations to come. The Van Andel Institute, under the research direction of Dr. George Vande Woude is a basic research institute focusing initially on cancer research. Dr. Vande Woude is an internationally recognized expert in Molecular Oncology, who came to the Van Andel Institute after having served as Director of the National Cancer Institute's Division of Basic Sciences. The Institute's Board of Scientific Advisors includes three Nobel Laureates and is chaired by Dr. Michael Brown of the University of Texas, Southwestern Medical School, and winner of the Nobel Prize for his work on Cholesterol Metabolism.

About Celera

Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, Md., is a definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera's generation, integration, and analysis of biological information. Celera intends to enable therapeutic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and

research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, Calif., and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800/762-6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," and "should," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) operating losses to date; (2) a unique and expanding business plan; (3) uncertainty of revenue growth; (4) unproven use of genomics information to develop products; (5) intense competition in the evolving genomics industry; (6) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (7) heavy reliance on strategic relationship with the Applied Biosystems Group; (8) lengthy sales cycle; (9) dependence on the unique expertise of its scientific and management staff; (10) dependence on computer hardware, software, and internet applications; (11) access to biological materials; (12) legal, ethical, and social issues affecting demand for products; (13) disruptions caused by rapid growth of the business; (14) government regulation of its products and services; (15) risks of future acquisitions; (16) uncertainty of outcome of stockholder litigation; and (17) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.

Note to Editors: Applera, Celera, Celera Genomics, and Celera Discovery System are trademarks and Applied Biosystems is a registered trademark of Applera Corporation or its subsidiaries in the US and certain other countries.